Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers (Uridine-GABA)

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Mclean Hospital
ClinicalTrials.gov Identifier:
NCT01261260
First received: December 14, 2010
Last updated: NA
Last verified: December 2010
History: No changes posted
  Purpose

On the dual basis of findings indicating GABA increases following acute and eight week SSRI/dopamine agonist administration and those indicating GABA-ergic effects following 14 day pyrimidine administration, the purpose of this study is to assess our following hypotheses:

  1. Relative to placebo, an oral dose of 1g of uridine BID for seven days will increase brain GABA levels in a sample of healthy, unmedicated adult males;
  2. Relative to placebo, an oral dose of 1g of uridine BID for seven days will increase NTP levels in a sample of healthy, unmedicated adult males; and
  3. Brain GABA levels will be directly correlated to high energy phosphate levels in this sample of healthy, unmedicated adult males.

Condition Intervention Phase
Healthy Male Subjects
Drug: Uridine
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Official Title: The Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers

Further study details as provided by Mclean Hospital:

Primary Outcome Measures:
  • Using MRI and MRS, after uridine administration an increase in brain GABA and NTP levels will be seen and increases in GABA and NTP will be correlated [ Time Frame: after 7 days of treatment ] [ Designated as safety issue: No ]
    This choice of time period will allow a determination of time course to efficacy between the acute and extended ranges, and further, because therapeutic dosage levels of uridine have yet to be established, in this and future studies we hope to determine the optimal dosage at which uridine increases brain GABA and ß-NTP levels.


Enrollment: 33
Study Start Date: November 2006
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Uridine
1g BID
Drug: Uridine
1 gram tablets BID for 7 days

Detailed Description:

Based on prior MRS studies by our group as well as the work of others, we hypothesize that oral administration of uridine will actuate an increase in brain gamma-amino butyric acid (GABA) levels, along with beta-nucleotide triphosphate (ß-NTP) levels, as compared with baseline. Our aim is to investigate this specific neuropharmacological effect and to demonstrate the suitability of a novel magnetic resonance spectroscopy protocol in so doing. Our rationale includes the consideration that the clinical utility of an intervention demonstrably effective in elevating brain GABA and high energy phosphate levels is broad, since lowered GABA and bioenergetic states are associated with a plurality of affective, anxiety, and substance use disorders.

On the dual basis of findings indicating GABA increases following acute and eight week SSRI/dopamine agonist administration and those noting GABA-ergic effects of 14 day pyrimidine administration, we hypothesize that an oral dose of 2g of uridine per day for seven days will increase brain GABA levels in a sample of healthy, unmedicated adult males. We also hypothesize that this 2g dose of uridine per day for 7 days will increase ß-NTP levels and, further, that the increase in GABA and high energy phosphate levels will be correlated. Of note, the phosphorylation of glutamic acid decarboxylase by ATP significantly increased the activity of this enzyme, which is reponsable for the synthesis of GABA. This choice of time period will allow a determination of time course to efficacy between the acute and extended ranges, and further, because therapeutic dosage levels of uridine have yet to be established, in this and future studies we hope to determine the optimal dosage at which uridine increases brain GABA and ß-NTP levels.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male
  • Age range of 18-60 years
  • BMI between 18.5 and 28
  • Medication-free
  • Capable of providing informed consent
  • Non- smoking for a minimum of one year

Exclusion Criteria:

  • Meets DSM-IV criteria for any Axis I disorder (past or present)
  • Global assessment of functioning (DSM IV TR) less than 50
  • Age less than 18 or greater than 60
  • BMI lower than 18.5 or higher than 28
  • Any history of Alcohol or substance dependence or abuse according to DSM-IV criteria (except for caffeine dependence)
  • Any medical condition which in the opinion of the investigator may have an effect on mood symptoms
  • Any individual who has a current mood disturbance (as defined by DSM-IV-R criteria)
  • Use of cigarettes or other nicotine-containing products
  • Allergy or other contraindication to uridine
  • Individuals unable to comply with instructions or procedures of study
  • History of significant head trauma
  • Claustrophobia or other contraindication to MRI (e.g., pacemaker, metal fragments)
  • Any illicit substance use in the past thirty days
  • Any past treatment for substance abuse
  • Any past hospitalization for mental illness.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01261260

Locations
United States, Massachusetts
McLean Hospital
Belmont, Massachusetts, United States, 02478
Sponsors and Collaborators
Mclean Hospital
Investigators
Principal Investigator: Perry F Renshaw, MD PhD The Brain Institute, University of Utah
  More Information

No publications provided

Responsible Party: Perry F. Renshaw MD PhD, Brain Institute, University of Utah
ClinicalTrials.gov Identifier: NCT01261260     History of Changes
Other Study ID Numbers: 2005-P-002083-McLean, 2R01MH058681-04A2
Study First Received: December 14, 2010
Last Updated: December 14, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Mclean Hospital:
uridine
gamma-amino butyric acid
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
Proton Echo-Planar Spectroscopic Imaging

ClinicalTrials.gov processed this record on August 28, 2014